Director Bruno Lucidi filed a Form 144 notice of proposed sale with the SEC on November 17, 2026, disclosing plans to sell 6,741 shares of Atea Pharmaceuticals, Inc. common stock following a same-day stock option exercise.

Key Highlights

  • Seller: Bruno Lucidi, a director of Atea Pharmaceuticals, Inc.
  • Shares proposed for sale: 6,741 shares of common stock
  • Aggregate market value: $27,189.82, according to the filing
  • Source of shares: Stock option exercise from the issuer, acquired November 17, 2026, with cash payment
  • Approximate date of sale: November 17, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services
  • Total shares outstanding: 80,304,145, as reported in the filing
  • Prior three-month sales: Nothing to report, per the filing

Lucidi's Proposed Sale Details at Atea Pharmaceuticals

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Bruno Lucidi, identified in the filing as a director of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR), disclosed a proposed sale of 6,741 shares of the company's common stock. The aggregate market value of the shares to be sold is listed as $27,189.82. The approximate date of sale is noted as November 17, 2026.

The filing states that the 6,741 shares were acquired on November 17, 2026, through a stock option exercise from the issuer, with cash listed as the nature of payment. The designated broker for the proposed transaction is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004. The securities are proposed to be sold on the NASDAQ exchange, as stated in the filing.

The filing reports no sales of Atea Pharmaceuticals securities by Lucidi during the past three months. By signing the notice, the filing states, Lucidi represented that he "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed." Atea Pharmaceuticals, Inc. is headquartered at 225 Franklin Street, Suite 2100, Boston, Massachusetts 02110.

What Was Disclosed

Atea Pharmaceuticals director Bruno Lucidi filed a Form 144 notice on November 17, 2026, disclosing a proposed sale of 6,741 common shares with an aggregate market value of $27,189.82, acquired the same day via stock option exercise, with no prior three-month sales reported.